OA11906A - Quinoline derivatives. - Google Patents

Quinoline derivatives. Download PDF

Info

Publication number
OA11906A
OA11906A OA00100011A OA00100011A OA11906A OA 11906 A OA11906 A OA 11906A OA 00100011 A OA00100011 A OA 00100011A OA 00100011 A OA00100011 A OA 00100011A OA 11906 A OA11906 A OA 11906A
Authority
OA
OAPI
Prior art keywords
methyl
chloro
quinoline
oxo
carboxamide
Prior art date
Application number
OA00100011A
Other languages
English (en)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of OA11906A publication Critical patent/OA11906A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
OA00100011A 1998-07-15 1999-07-14 Quinoline derivatives. OA11906A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802549A SE9802549D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives

Publications (1)

Publication Number Publication Date
OA11906A true OA11906A (en) 2006-04-10

Family

ID=20412093

Family Applications (1)

Application Number Title Priority Date Filing Date
OA00100011A OA11906A (en) 1998-07-15 1999-07-14 Quinoline derivatives.

Country Status (33)

Country Link
EP (1) EP1095021B1 (xx)
JP (1) JP4045070B2 (xx)
KR (1) KR100516382B1 (xx)
CN (1) CN1157378C (xx)
AP (1) AP1366A (xx)
AT (1) ATE250036T1 (xx)
AU (1) AU751103B2 (xx)
BR (1) BR9912109B1 (xx)
CA (1) CA2336968C (xx)
CZ (1) CZ300229B6 (xx)
DE (1) DE69911415T2 (xx)
DK (1) DK1095021T3 (xx)
EE (1) EE04673B1 (xx)
ES (1) ES2205854T3 (xx)
HK (1) HK1035715A1 (xx)
HR (1) HRP20010039B1 (xx)
HU (1) HU229427B1 (xx)
ID (1) ID27423A (xx)
IL (2) IL140346A0 (xx)
IS (1) IS2208B (xx)
ME (1) MEP57408A (xx)
NO (1) NO317601B1 (xx)
NZ (1) NZ508923A (xx)
OA (1) OA11906A (xx)
PL (1) PL199783B1 (xx)
PT (1) PT1095021E (xx)
RS (1) RS50128B (xx)
RU (1) RU2213733C2 (xx)
SE (1) SE9802549D0 (xx)
TR (1) TR200100087T2 (xx)
UA (1) UA64791C2 (xx)
WO (1) WO2000003991A1 (xx)
ZA (1) ZA200007593B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
RS51019B (sr) * 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
US20060100257A1 (en) * 2002-06-05 2006-05-11 Susumu Muto Inhibitors against the activation of ap-1 and nfat
JP4635130B2 (ja) * 2002-06-11 2011-02-16 株式会社医薬分子設計研究所 神経変性疾患治療剤
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
CN101291911B (zh) 2005-10-19 2014-08-13 泰华制药工业有限公司 拉奎尼莫钠晶体及其制备方法
MX2008015808A (es) 2006-06-12 2009-02-17 Teva Pharma Preparaciones de laquinimod estable.
WO2008113006A1 (en) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
PT2234485E (pt) 2007-12-20 2014-02-17 Teva Pharma Preparações de laquinimod estáveis
UA104005C2 (ru) 2008-09-03 2013-12-25 Тева Фармасьютикл Индастриз, Лтд. 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
RS54707B1 (en) 2009-07-30 2016-08-31 Teva Pharmaceutical Industries Ltd. TREATMENT OF CROWN LAKVINIMOD DISEASE
PT2467372T (pt) 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
AU2011223697B2 (en) 2010-03-03 2016-07-14 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
PE20130613A1 (es) 2010-03-03 2013-06-23 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
TWI552750B (zh) * 2010-08-27 2016-10-11 歌林達股份有限公司 作為ｋｃｎｑ２／３鉀離子通道調節劑之經取代之２－氧基－及2－硫基－二氫喹啉－３－羧醯胺
US8962598B2 (en) 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
AU2012322706A1 (en) 2011-10-12 2014-05-22 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EA201491460A1 (ru) 2012-02-03 2015-01-30 Тева Фармасьютикал Индастриз Лтд. ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
JP5868839B2 (ja) 2012-12-27 2016-02-24 三菱重工業株式会社 チャー払出管
SG11201506409RA (en) 2013-03-14 2015-09-29 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN105367492B (zh) * 2014-08-28 2018-07-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
CN107108510B (zh) 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
EA031643B1 (ru) 2014-11-19 2019-01-31 Эктив Байотек Аб Применение тасквинимода для лечения острого лимфобластного лейкоза и острого миелоидного лейкоза
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
WO2018105943A1 (ko) * 2016-12-07 2018-06-14 순천향대학교 산학협력단 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물
EP4114368A1 (en) 2020-03-03 2023-01-11 Active Biotech AB Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
CA3185531A1 (en) 2020-07-23 2022-01-27 Rebekka Katharina Marita SCHNEIDER-KRAMANN S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
IL308542A (en) 2021-05-25 2024-01-01 Active Biotech Ab Multiparticles of tesquinimod and their use
CN117500790A (zh) 2021-07-02 2024-02-02 活跃生物技术有限公司 含有他喹莫德的药物产品和用于评估所述产品的纯度的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
JPH07224040A (ja) * 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
HUP0103224A2 (hu) 2002-01-28
BR9912109A (pt) 2001-05-02
EP1095021A1 (en) 2001-05-02
CZ200194A3 (en) 2001-05-16
BR9912109B1 (pt) 2012-08-21
HUP0103224A3 (en) 2002-11-28
EE200100010A (et) 2002-06-17
RS50128B (sr) 2009-03-25
NO20010211L (no) 2001-03-15
CZ300229B6 (cs) 2009-03-25
NO20010211D0 (no) 2001-01-12
KR20010053115A (ko) 2001-06-25
DK1095021T3 (da) 2003-11-24
AU4950499A (en) 2000-02-07
CN1309641A (zh) 2001-08-22
IL140346A (en) 2006-07-05
TR200100087T2 (tr) 2001-06-21
DE69911415D1 (de) 2003-10-23
ID27423A (id) 2001-04-05
JP2002520395A (ja) 2002-07-09
WO2000003991A1 (en) 2000-01-27
HU229427B1 (en) 2013-12-30
AP2001002041A0 (en) 2001-03-31
AP1366A (en) 2005-01-26
CN1157378C (zh) 2004-07-14
DE69911415T2 (de) 2004-07-08
HK1035715A1 (en) 2001-12-07
RU2213733C2 (ru) 2003-10-10
JP4045070B2 (ja) 2008-02-13
ATE250036T1 (de) 2003-10-15
NZ508923A (en) 2002-09-27
ME00374B (me) 2011-05-10
EP1095021B1 (en) 2003-09-17
PL345388A1 (en) 2001-12-17
KR100516382B1 (ko) 2005-09-26
AU751103B2 (en) 2002-08-08
YU1501A (sh) 2003-10-31
NO317601B1 (no) 2004-11-22
IS5775A (is) 2000-12-18
PT1095021E (pt) 2003-12-31
SE9802549D0 (sv) 1998-07-15
IS2208B (is) 2007-02-15
CA2336968C (en) 2005-08-30
CA2336968A1 (en) 2000-01-27
HRP20010039A2 (en) 2001-12-31
UA64791C2 (en) 2004-03-15
ES2205854T3 (es) 2004-05-01
IL140346A0 (en) 2002-02-10
ZA200007593B (en) 2001-07-09
MEP57408A (en) 2011-05-10
PL199783B1 (pl) 2008-10-31
EE04673B1 (et) 2006-08-15
HRP20010039B1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
US6133285A (en) Quinoline derivatives
EP1095021B1 (en) Quinoline derivatives
AP1293A (en) Quinoline derivatives.
US6077851A (en) Quinoline derivatives
US6121287A (en) Quinoline derivatives
AU745915B2 (en) Quinoline derivatives
MXPA01000388A (en) Quinoline derivatives
MXPA00009954A (en) Quinoline derivatives